Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year price target among […]